Literature DB >> 29064243

Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Ross W Cheloha1, Bingming Chen2, Niyanta N Kumar2, Tomoyuki Watanabe3, Robert G Thorne2,4,5,6, Lingjun Li1,2, Thomas J Gardella3, Samuel H Gellman1.   

Abstract

The parathyroid hormone receptor 1 (PTHR1) is a member of the B-family of GPCRs; these receptors are activated by long polypeptide hormones and constitute targets of drug development efforts. Parathyroid hormone (PTH, 84 residues) and PTH-related protein (PTHrP, 141 residues) are natural agonists of PTHR1, and an N-terminal fragment of PTH, PTH(1-34), is used clinically to treat osteoporosis. Conventional peptides in the 20-40-mer length range are rapidly degraded by proteases, which may limit their biomedical utility. We have used the PTHR1-ligand system to explore the impact of broadly distributed replacement of α-amino acid residues with β-amino acid residues on susceptibility to proteolysis and agonist activity. This effort led us to identify new PTHR1 agonists that contain α → β replacements throughout their sequences, manifest potent agonist activity in cellular assays, and display remarkable resistance to proteolysis, in cases remaining active after extended exposure to simulated gastric fluid. The strategy we have employed suggests a path toward identifying protease-resistant agonists of other B-family GPCRs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29064243      PMCID: PMC6016400          DOI: 10.1021/acs.jmedchem.7b00876

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  94 in total

1.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

2.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

Review 3.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 4.  Insights into the structure of class B GPCRs.

Authors:  Kaspar Hollenstein; Chris de Graaf; Andrea Bortolato; Ming-Wei Wang; Fiona H Marshall; Raymond C Stevens
Journal:  Trends Pharmacol Sci       Date:  2013-12-18       Impact factor: 14.819

5.  Residue-Based Preorganization of BH3-Derived α/β-Peptides: Modulating Affinity, Selectivity and Proteolytic Susceptibility in α-Helix Mimics.

Authors:  Kimberly J Peterson-Kaufman; Holly S Haase; Melissa D Boersma; Erinna F Lee; W Douglas Fairlie; Samuel H Gellman
Journal:  ACS Chem Biol       Date:  2015-05-07       Impact factor: 5.100

Review 6.  Endosomal generation of cAMP in GPCR signaling.

Authors:  Jean-Pierre Vilardaga; Frederic G Jean-Alphonse; Thomas J Gardella
Journal:  Nat Chem Biol       Date:  2014-09       Impact factor: 15.040

7.  Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array.

Authors:  Lisa M Johnson; David E Mortenson; Hyun Gi Yun; W Seth Horne; Thomas J Ketas; Min Lu; John P Moore; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-04-23       Impact factor: 15.419

8.  A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo.

Authors:  Maruti Uppalapati; Dong Jun Lee; Kalyaneswar Mandal; Hongyan Li; Les P Miranda; Joshua Lowitz; John Kenney; Jarrett J Adams; Dana Ault-Riché; Stephen B H Kent; Sachdev S Sidhu
Journal:  ACS Chem Biol       Date:  2016-02-03       Impact factor: 5.100

Review 9.  Parathyroid hormone: a double-edged sword for bone metabolism.

Authors:  Ling Qin; Liza J Raggatt; Nicola C Partridge
Journal:  Trends Endocrinol Metab       Date:  2004-03       Impact factor: 12.015

10.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

View more
  7 in total

1.  Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.

Authors:  Brian P Cary; Marlies V Hager; Samuel H Gellman
Journal:  Chembiochem       Date:  2019-09-20       Impact factor: 3.164

Review 2.  PTH/PTHrP Receptor Signaling, Allostery, and Structures.

Authors:  Ieva Sutkeviciute; Lisa J Clark; Alex D White; Thomas J Gardella; Jean-Pierre Vilardaga
Journal:  Trends Endocrinol Metab       Date:  2019-11       Impact factor: 12.015

3.  Receptor selectivity from minimal backbone modification of a polypeptide agonist.

Authors:  Shi Liu; Ross W Cheloha; Tomoyuki Watanabe; Thomas J Gardella; Samuel H Gellman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-15       Impact factor: 11.205

4.  Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism.

Authors:  Shi Liu; Frederic G Jean-Alphonse; Alex D White; Denise Wootten; Patrick M Sexton; Thomas J Gardella; Jean-Pierre Vilardaga; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2019-09-09       Impact factor: 15.419

5.  Improved GPCR ligands from nanobody tethering.

Authors:  Ross W Cheloha; Fabian A Fischer; Andrew W Woodham; Eileen Daley; Naomi Suminski; Thomas J Gardella; Hidde L Ploegh
Journal:  Nat Commun       Date:  2020-04-29       Impact factor: 14.919

6.  Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking.

Authors:  Juliette Fremaux; Claire Venin; Laura Mauran; Robert Zimmer; Florian Koensgen; Didier Rognan; Stavroula Bitsi; Maria A Lucey; Ben Jones; Alejandra Tomas; Gilles Guichard; Sébastien R Goudreau
Journal:  Chem Sci       Date:  2019-09-11       Impact factor: 9.825

7.  Proteomimetic surface fragments distinguish targets by function.

Authors:  Attila Tököli; Beáta Mag; Éva Bartus; Edit Wéber; Gerda Szakonyi; Márton A Simon; Ágnes Czibula; Éva Monostori; László Nyitray; Tamás A Martinek
Journal:  Chem Sci       Date:  2020-09-10       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.